Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955486 | 1.00 | TTR (0.42) | TTRNOTUMMGLLGRIN2BPDE3A | |
| SCHEMBL508251 | 0.86 | TTR (0.46) | TTRMGLLGRIN2BENPP2ABL1 | |
| SCHEMBL13065401 | 0.85 | TTR (0.39) | TTRNOTUMMGLLENPP2ABL1 | |
| SCHEMBL29952898 | 0.80 | APP (0.45) | MGLLENPP2ABL1CA1CA2 | |
| SCHEMBL31437950 | 0.80 | MGLL (0.39) | TTRMGLLENPP2ABL1CA1 | |
| SCHEMBL1496432 | 0.80 | MGLL (0.39) | TTRMGLLENPP2ABL1CA1 | |
| SCHEMBL22683815 | 0.80 | APP (0.45) | MGLLENPP2ABL1CA1CA2 | |
| SCHEMBL29953617 | 0.79 | MGLL (0.38) | TTRNOTUMMGLLENPP2ABL1 | |
| SCHEMBL20638904 | 0.77 | ENPP2 (0.41) | MGLLENPP2ABL1CA1CA2 | |
| SCHEMBL29953216 | 0.77 | ENPP2 (0.41) | MGLLGRIN2BENPP2ABL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011068211-A1 | 2-PYRIDONE COMPOUNDS | 大正製薬株式会社 (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1844013-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1841736-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077364-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | TTR 719/4885NOTUM 4253/4885MGLL 3910/4885 |
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | TTR 818/4885NOTUM 4246/4885MGLL 4091/4885 |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | TTR 945/4885NOTUM 4119/4885MGLL 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.